Detail of "202138-50-9"

CAS Number:
202138-50-9
Name:
Tenofovir disoproxil fumarate
Molecular Structure:
Formula:
C₁₉H₃₀N₅O₁₀P^.C₄H₄O₄
Molecular Weight:
635.51
Synonyms:
TDF;PMPA prodrug;Tenofovir Disoproxil Fumarate [USAN];9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl)adenine, fumarate;201341-05-1;Bis(NeopentylOC)PMPA;Viread;GS 4331-05 (*1:1 Fumarate salt*);Viread (*1:1 Fumarate salt*);Truvada;Tenofovir DF;[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(propan-2-yloxycarbonyloxymethoxy)phosphoryl]oxymethyl propan-2-yl carbonate;
Density:
1.45 g/cm³
Boiling Point:
642.7 °C at 760 mmHg
Flash Point:
342.5 °C
Hazard Symbols:
Xi
Risk Codes:
36/37/38
Safety:
26-36 Details
particular:
particular

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

All Suppliers

Page：1/2

Supplier Location
Supplier Location
- China (Mainland)(37)
- India(2)
- United States(1)
Business Type
Business Type
- Lab/Research institutions(6)
- Manufacturers(1)
- Trading Company(26)
Certificates
Certificates
- ISO(2)
- Production License (0)
Exhibitions
Exhibitions
- CPhI China

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

CAS No.202138-50-9 Tenofovir disoproxil fumarate

Assay:NLT98.5% Appearance:White or alm... Package:Aluminum foi...Storage:Store at 2-8... Transportation:Suitable for... Application:Antiviral ...

TENOFOVIR DISOPROXIC;9-((R)-2-((Bis(((isopropoxycarbonyl)oxy)methoxy)phosphinyl)methoxy)propyl

Supplier:Beijing Zhongshuo Pharmaceutical T & D Co.,Ltd[ China (Mainland)]

Verified-Silver Supplier 1st Year Silver
Supplier 380 Integral
380

Contact:Ms. Wang

Tel:0086-10-64430626

Fax:0086-10-64439981

Address:23B Shenfang Building,4 Area AnZhenXiLi,ChaoYang District,Beijing

Contact Suppliers

Total:40 Page 1 of 2 1 2 Next>>

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

Tenofovir-related nephrotoxicity in HIV-infected patients: Tenofovir-related nephrotoxicity in HIV-infected patients. Comments. Barrios, Ana; Garcia-Benayas, Teresa; Gonzalez-Lahoz, Juan; Soriano, Vincent (Hospital Carlos III, Service of Infectious Diseases, Madrid, Spain). AIDS (London, United Kingdom), 18(6), 960-963 (English) 2004 Lippincott Williams & Wilkins. CODEN: AIDSET. ISSN: 0269-9370. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. An HIV-infected patient who developed acute renal failure assocd.Several substances like 202138-50-9 may be metioned in this study. with tenofovir disoproxil fumarate (TDF) is described. Several facts support the involvement of TDF in the development of renal dysfunction in this patient. First, acute renal failure occurred soon after TDF was initiated. Second, the patient had no previous renal dysfunction and TDF was the only new agent added before renal abnormalities appeared. Third, blood and urine analyses were similar to those reported in other cases from the literature. As expected, the discontinuation of TDF led to the normalization of renal function. .

Resistance Issues With New Nucleoside/Nucleotide Backbone Options: Resistance Issues With New Nucleoside/Nucleotide Backbone Options. Wainberg, Mark A.; Turner, Dan (McGill University AIDS Centre, Montreal, Can.). JAIDS, Journal of Acquired Immune Deficiency Syndromes, 37(Suppl. 1), S36-S43 (English) 2004 Lippincott Williams & Wilkins. CODEN: JJASFJ. ISSN: 1525-4135. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. The nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs/NtRTIs) remain an enduring feature of combination therapy. As NRTI/NtRTI options continue to expand, questions arise about how best to combine these agents to create effective dual NRTI/NtRTI backbones in antiretroviral regimens while avoiding treatment-emergent drug resistance. Clinicians must consider how NRTIs/NtRTIs such as tenofovir DF (TDF), abacavir (ABC), and emtricitabine (FTC), as well as new once-daily and coformulated NRTIs/NtRTIs, interact with older agents when combined in novel regimens and how sequencing the new NRTIs can preserve future treatment options. Resistance data from clin. trials have revealed important information on the patterns, prevalence, and effects of resistance seen among patients experiencing virol. failure. In recent years, the prevalence of some mutations such as M184V and Q151M has remained relatively const., while the L74V mutation, the 69 insertions, and thymidine analog mutations have decreased in prevalence. Other mutations such as K65R and Y115F, while still relatively uncommon, are increasing in prevalence. This increase may be due to the use of new treatment combinations that select for these mutations at a higher rate. Clin. trials suggest that new regimens contg. TDF or ABC select for K65R and that this mutation is obsd. more frequently with TDF; in contrast, L74V is obsd. more frequently in ABC-contg. regimens but is not commonly selected by TDF-contg.There are some commonly used reagents with their cas registry numbers 202138-50-9 and 136470-78-5 in this article. regimens. Several lines of evidence are converging to suggest that the presence of zidovudine may decrease the risk of L74V and K65R in ABC- or TDF-contg. regimens. This review summarizes the clin. implications of resistance profiles assocd. with new NRTI/NtRTI regimens in current use and in advanced clin. studies. .

Detail of "202138-50-9"

Tenofovir disoproxil fumarate

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

Exhibitions

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir Disoproxil Fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

CAS No.202138-50-9 Tenofovir disoproxil fumarate

Reference